GHRP-2 + CJC-1295 Peptide Stack

The integration of GHRP-2 and CJC-1295 in a single research stack is designed to maximize the release of growth hormone through distinct yet complementary mechanisms. GHRP-2 is recognized for its selective action among growth hormone secretagogues, exhibiting a more favorable profile in terms of appetite stimulation compared to GHRP-6. This selectivity allows for targeted research into GH's role in various biological processes without the confounding effects of increased hunger. The combination with CJC-1295 further enhances the stack's efficacy by promoting sustained GH release, thereby providing a robust platform for studying the physiological impacts of growth hormone and its downstream effects on tissue growth and metabolism.

GHRP-2, also known as pralmorelin, is a synthetic hexapeptide that serves as a potent growth hormone secretagogue, specifically activating the ghrelin receptor (GHS-R) to stimulate GH release. The molecular composition of GHRP-2 (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817.97 g/mol) allows it to elicit a strong, dose-dependent response in GH secretion. Research indicates that GHRP-2 not only produces a significant GH release but does so with less appetite stimulation than its analogs, making it particularly useful in clinical and preclinical studies. Its diagnostic application in Japan for GH deficiency highlights its clinical relevance, with studies demonstrating a safety profile comparable to placebo when administered at therapeutic doses. Mechanistically, GHRP-2 binds to GHS-R on pituitary somatotrophs, inducing a pulsatile release of GH while maintaining physiological feedback mechanisms, thus avoiding the rapid receptor desensitization seen with more frequent dosing regimens.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has garnered attention for its potential in research settings, particularly concerning its role in GH regulation. Developed initially for the treatment of HIV-associated lipodystrophy, CJC-1295 exists in two forms: one with a Drug Affinity Complex (DAC) that extends its half-life significantly, and another variant, Mod GRF 1-29, which mimics the natural pulsatile release of GHRH. Clinical trials, such as those conducted by Teichman et al. in 2006, have shown that CJC-1295 can induce substantial increases in both GH and IGF-1 levels, demonstrating its efficacy in healthy adults. The mechanism of action involves binding to GHRH receptors, leading to enhanced transcription of the GH gene and subsequent release of GH. While the DAC version provides prolonged GH elevation, it may also risk receptor desensitization and metabolic complications. In contrast, Mod GRF 1-29 is designed to maintain a physiological release pattern, thereby reducing potential side effects and preserving the negative feedback mechanisms that regulate GH levels.